Q3 EPS Estimates for Spyglass Pharma Cut by HC Wainwright

Spyglass Pharma, Inc. (NASDAQ:SGP) – Analysts at HC Wainwright reduced their Q3 2026 EPS estimates for Spyglass Pharma in a research note issued to investors on Friday, August 7th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.63) per share for the quarter, down from their prior forecast of ($0.50). The consensus estimate for Spyglass Pharma’s current full-year earnings is ($2.00) per share. HC Wainwright also issued estimates for Spyglass Pharma’s Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($2.52) EPS, Q1 2027 earnings at ($0.64) EPS, Q2 2027 earnings at ($0.64) EPS, Q3 2027 earnings at ($0.64) EPS, Q4 2027 earnings at ($0.64) EPS and FY2027 earnings at ($2.57) EPS.

Separately, Weiss Ratings started coverage on shares of Spyglass Pharma in a report on Thursday. They issued a “sell (e)” rating for the company. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Spyglass Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.00.

Spyglass Pharma Stock Performance

Shares of SGP opened at $25.16 on Tuesday. The business’s fifty day simple moving average is $20.38. The firm has a market cap of $841.10 million and a PE ratio of -3.93. Spyglass Pharma has a 52-week low of $17.06 and a 52-week high of $32.44.

Spyglass Pharma (NASDAQ:SGP) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.11).

Institutional Investors Weigh In On Spyglass Pharma

A number of institutional investors have recently modified their holdings of SGP. First Light Asset Management LLC purchased a new position in Spyglass Pharma during the 1st quarter valued at about $9,716,000. Affinity Asset Advisors LLC acquired a new stake in shares of Spyglass Pharma during the first quarter worth about $6,478,000. Monashee Investment Management LLC purchased a new position in shares of Spyglass Pharma in the first quarter valued at approximately $2,461,000. Bank of America Corp DE acquired a new position in shares of Spyglass Pharma in the first quarter valued at approximately $726,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Spyglass Pharma in the second quarter valued at approximately $533,000.

About Spyglass Pharma

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).